Japan's Ministry of Health has approved Sanofi's CirCLIQ Injector, developed with Enable Injections' enFuse On-Body Delivery System, for administering Sarclisa subcutaneous formulation to treat multiple myeloma. This marks Enable's first commercial product approval in Japan and the first anticancer treatment delivered via an on-body injector in the country. The approval covers use in combination with standard regimens for both relapsed/refractory and newly diagnosed multiple myeloma patients. This expands Enable's global reach following prior approvals in the US and Europe and supports more convenient, innovative cancer treatment delivery.
Sanofi's stock trades at USD 40.09 on Pluang as of Oct 19, 2026 19:12 WIB, near its 52-week low of USD 39.12 and well below its 52-week high of USD 52.34. Despite the recent approval news, the stock is down 1.28% for the day, with a market cap of $96.64 billion and a dividend yield of 5.96%. This places Sanofi in a cautious position compared to its yearly range, reflecting current investor sentiment on the platform.
Sanofi has begun construction of a cutting-edge insulin manufacturing facility at its BioCampus in Frankfurt, Germany, aiming for full production by 2032. This new plant will enhance Sanofi's ability to supply insulin reliably to millions worldwide, ...
Novavax stock dropped 12% due to heavy selling pressure on vaccine makers, with Moderna also falling 10% while Pfizer remained stable. Novavax depends on Sanofi to commercialize its COVID vaccine, making its revenue reliant on Sanofi's rollout and mi...
Recursion Pharmaceuticals announced a $200 million oversubscribed follow-on stock offering backed by major healthcare investors. The company reported promising Phase 1b/2 data for REC-4881 showing significant and durable reductions in precancerous po...
